Alaunos Raises $1.12M in Registered Direct Offering at $1.46/Share
TCRT sits 29% above its 52-week low of $1.28 on elevated volume (60× avg).
Summary
Alaunos Therapeutics priced a registered direct offering of 380,469 common shares plus pre-funded warrants for 386,654 shares at $1.46 per share, raising about $1.12 million before fees. The deal is expected to close September 21, 2026. This follows the company's critical cash position of $0.35 million reported in its last 10-Q, which was only sufficient into Q2 2026. The offering is highly dilutive relative to the company's tiny market cap of roughly $4 million, but it provides essential near-term funding. Proceeds are earmarked for general working capital. The at-the-market pricing under Nasdaq rules suggests the company is taking advantage of its current share price to shore up liquidity.
At the time of this announcement, TCRT was trading at $1.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $1.28 to $4.59. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.